News und Analysen
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease
Regulatory News:
Sensorion, (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
Valbiotis gibt den letzten Besuch des letzten Patienten in der Phase II/III REVERSE-IT Studie zu TOTUM•63 in Partnerschaft mit Nestlé Health Science bekannt
Valbiotis (FR0013254851 - ALVAL, PEA / SME förderungswürdig (Paris:ALVAL), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has
Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its
Vistagen to Present at Cowen 43rd Annual Health Care Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis veröffentlicht Brief an die Aktionäre und Finanzkommunikationskalender für 2023
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA / KMU-qualifiziert), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich auf wissenschaftliche Innovationen
Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating
Sensorion announces R&D Day focusing on its Gene Therapy programs
Regulatory News:
Sensorion, (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and
Lysogene Announces the Extension of Deadline for the Submission of Offers
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial
Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating
EQS-Adhoc: Elanix Biotechnologies AG: RESIGNATION AND NOMINATION IN THE SUPERVISORY BOARD
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Relief Therapeutics Provides an Update on its Financing Strategy
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
EQS-News: Centaur Pharmaceuticals Pvt Ltd increases sales with Woxheal® - ongoing open label marketing study in numerous Indian centres AG:
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous